The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).
Miriam Koopman
No relevant relationships to disclose
Lieke HJ Simkens
No relevant relationships to disclose
Albert J. Ten Tije
Consultant or Advisory Role - Roche
Geert-Jan Creemers
No relevant relationships to disclose
Olaf JL Loosveld
No relevant relationships to disclose
Felix E. de Jongh
No relevant relationships to disclose
Frans Erdkamp
No relevant relationships to disclose
Zoran Erjavec
No relevant relationships to disclose
Adelheid ME van der Torren
No relevant relationships to disclose
Jacobus JM Van der Hoeven
No relevant relationships to disclose
Peter Nieboer
No relevant relationships to disclose
J. J. Braun
No relevant relationships to disclose
Rob L. Jansen
No relevant relationships to disclose
Janny G. Haasjes
No relevant relationships to disclose
Annemieke Cats
No relevant relationships to disclose
Jacob J. Wals
No relevant relationships to disclose
Linda Mol
No relevant relationships to disclose
Otilia Dalesio
No relevant relationships to disclose
Harm van Tinteren
No relevant relationships to disclose
Cornelis J. A. Punt
Consultant or Advisory Role - Roche